Aurobindo Pharma's Q1 FY 2025-26 Quarter Results

Result Summary

• Aurobindo Pharma Ltd reported a 3.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 2.4%.
• Its expenses for the quarter were up by 6.6% QoQ and 4.7% YoY.
• The net profit decreased 9.2% QoQ and decreased 10.2% YoY.
• The earnings per share (EPS) of Aurobindo Pharma Ltd stood at 14.2 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Aurobindo Pharma Ltd is a prominent player in the pharmaceutical industry, known for its robust portfolio of formulations, generic drugs, and active pharmaceutical ingredients (APIs). Established in 1986, the company has carved a niche in the global pharmaceutical market, offering a diverse range of products spanning several therapeutic categories including antibiotics, anti-retrovirals, and cardiovascular drugs. Aurobindo Pharma operates across major international markets with an emphasis on research and development to drive innovation. The company is headquartered in Hyderabad, India, and has a significant global footprint with manufacturing and research facilities designed to comply with stringent international regulatory standards. Recent developments for the company include strategic acquisitions to expand its product offerings and enhance market reach, though specific details are not available from the provided data.

Revenue

For the first quarter of fiscal year 2026 (Q1FY26), Aurobindo Pharma Ltd reported a total income of ₹7973.44 crores, reflecting a quarter-over-quarter (QoQ) increase of 3.3% from the ₹7715.77 crores recorded in Q4FY25. This growth is also seen year-over-year (YoY), with an increase of 2.4% from the ₹7787.95 crores reported in Q1FY25. The consistent rise in total income over these periods suggests a stable revenue stream. The company's ability to maintain growth in revenue indicates a strong market presence and possibly successful product performance.

Profitability

The Profit Before Tax (PBT) for Q1FY26 was ₹1204.88 crores, which represents a decrease of 3.0% QoQ from ₹1242.56 crores in Q4FY25 and a more significant drop of 9.1% YoY from ₹1325.28 crores in Q1FY25. This decline in profit before tax is accompanied by a tax expense of ₹382.60 crores for Q1FY26, which increased by 18.6% QoQ from ₹322.55 crores in Q4FY25, yet decreased by 5.7% YoY from ₹405.67 crores in Q1FY25. Consequently, the Profit After Tax (PAT) for Q1FY26 was ₹824.20 crores, marking a decrease of 9.2% QoQ from ₹907.35 crores in Q4FY25 and 10.2% YoY from ₹918.22 crores in Q1FY25. Earnings Per Share (EPS) also fell to ₹14.20 in Q1FY26 from ₹15.50 in Q4FY25 and ₹15.70 in Q1FY25, reflecting a decline of 8.4% QoQ and 9.6% YoY.

Operating Metrics

The fiscal performance of Aurobindo Pharma Ltd in Q1FY26 reveals total expenses amounting to ₹6768.56 crores, an increase of 6.6% QoQ from ₹6351.10 crores in Q4FY25 and 4.7% YoY from ₹6462.67 crores in Q1FY25. This upward trend in expenses may suggest increased operational costs or investments. The company's profit margins have been compressed as indicated by the reduction in both Profit Before Tax and Profit After Tax, despite the growth in total income. The financial data shows a notable increase in tax expenses on a QoQ basis, which impacts the overall net profit. The earnings per share also reflect the downward trend in net profitability over the analyzed periods.